Quarterly ResultMay 7, 2026, 07:02 AM
Quantum BioPharma Files IND for Lucid-MS Phase 2 Trial; Q1 Liquidity Up
AI Summary
Quantum BioPharma Ltd. reported strong financial and operational results for Q1 2026, significantly strengthening its liquidity position and reducing cash burn. The company's cash and digital assets more than doubled to $9.8 million, providing a runway until July 2027. A major milestone was achieved with the formal submission of an IND application to the US FDA for its Lucid-MS Phase 2 clinical trial for multiple sclerosis. Additionally, Quantum's subsidiary Unbuzzd completed a corporate reorganization, and a lawsuit against CIBC and RBC for alleged market manipulation advanced in Quantum's favor.
Key Highlights
- Cash, cash equivalents, and digital assets totaled $9.8 million as of March 31, 2026, more than doubling from $4.1 million.
- Current liquidity is sufficient to fund planned operations to approximately July 2027.
- Cash used in operating activities decreased by 60% to $1.66 million in Q1 2026.
- Filed an Investigational New Drug (IND) application with the US FDA for Lucid-MS Phase 2 clinical trial in Multiple Sclerosis.
- Appointed Dr. Salvatore Napoli as principal investigator and signed LOI with Allucent for Lucid-MS Phase 2 trial.
- Unbuzzd completed corporate reorganization and hired a new CEO to launch IPO financing and commercialization.
- US District Court ruled against CIBC and RBC's motion to dismiss Quantum's market manipulation lawsuit.